ncibtep@nih.gov

Bioinformatics Training and Education Program

Single Cell Metabolomics: Computational Science in Immuno-Oncology

Single Cell Metabolomics: Computational Science in Immuno-Oncology

 When: Oct. 26th, 2022 2:30 pm - 3:30 pm

To Know

Where:
Online Webinar
Organizer:
CBIIT
This class has ended.

About this Class

In partnership with NCI’s Cancer MoonshotSM Initiative, the Society for Immunotherapy of Cancer (SITC) and the Big Data and Data Sharing Committee are hosting the eighth of nine webinars that make up the 2022 SITC-NCI Computational Immuno-Oncology Webinar Series. Dr. Theodore Alexandrov of European Molecular Biology Laboratory will present, “Single Cell Metabolomics: Computational Science in Immuno-Oncology” with moderation by Dr. Dora Hammerl of Erasmus MC Cancer Institute. Dr. Alexandrov will highlight emerging, single-cell metabolomics technology for profiling the metabolism of individual cells. Such highlights include:
  • key aspects,
  • challenges, and
  • perspectives on how this technology could advance research tools for drug and therapy development.
The SITC-NCI Computational Immuno-Oncology Webinar Series consists of nine, hour-long courses featuring a moderator and faculty speaker to lead instruction. Topics will cover a host of computational challenges of analyzing and integrating diverse assay data across the spectrum of immuno-oncology. This series is intended for scientists early in their careers and/or those who want to remain abreast of the latest technologies. These webinars were created to foster better communication concerning data science technologies and analyses between cancer immunotherapy researchers and clinicians to advance translational immunotherapy research. Speakers: Theodore Alexandrov, Ph.D. Dr. Alexandrov is head of the metabolomics core facility and team leader at European Molecular Biology Laboratory, in addition to being a group leader in the Molecular Medicine Partnership Unit. Dora Hammerl, Ph.D. Dr. Hammerl joined the Debets Laboratory at Erasmus MC Cancer Institute where she received her doctorate in 2020. She is the co-founder and vice president of research and development at Pan Cancer T, a company dedicated to developing T cell receptor (TCR) T cell therapies.